Contract facts
Small businessNo full NAICS 541714 intel page yet. Browse NAICS intelligence
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U is a federal Small business award for National Institutes Of Health Niaid held by Collaborations Pharmaceuticals Inc. Estimated value $2M ($2M obligated). Current period of performance ends Dec 29, 2026. Last award drew 4 bidders. Place of performance: RALEIGH NC. Related solicitation PHS 2025-1.
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U
Recompete timing
PublicCurrent PoP ends Dec 29, 2026 (93 days remaining). Agencies typically plan 12–18 months ahead — at 3.1 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75N93025C00039? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordCollaborations Pharmaceuticals Inc — $2.0M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N93025C00039?
75N93025C00039 (IS to develop pan-influenza inhibitors targeting) is a National Institutes Of Health Niaid award with a potential value of $2M, currently held by Collaborations Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N93025C00039?
National Institutes Of Health Niaid awarded 75N93025C00039 to Collaborations Pharmaceuticals Inc (potential $2M).
Who is the incumbent on 75N93025C00039?
Collaborations Pharmaceuticals Inc is the incumbent with $2.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 29, 2026.
When does Collaborations Pharmaceuticals Inc’s 75N93025C00039 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75N93025C00039? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.